82,3 % des co-infectés étaient traités par ténofovir. 
Résultats. -Au total, 2 097 patients ont été inclus (âge médian de 37 ans, 65,4 % de femmes).
Le dépistage de l'hépatite B a été réalisé chez 313 (14,9 %) patients, avec une augmentation As both infections share the same contamination routes (blood or sexual routes, or mother-tochild transmission), HIV-HBV co-infection is frequent, with 8-25% of HIV-infected patients who also present with chronic HBV infection in Sub-Saharan Africa [9] [10] [11] [12] [13] [14] [15] . HIV-HBV co-infected patients are at higher risk of death, poor immune reconstitution, and hepatotoxicity on antiretroviral therapy (ART) than patients only presenting with HIV infection [16] [17] [18] [19] [20] .
WHO has been recommending since 2010 the systematic HBV screening in HIV-infected patients before ART initiation. Most national HIV/AIDS programs have now integrated this recommendation. HBV status ascertainment in HIV-infected patients is very important as it helps optimize the management of HIV-HBV co-infected patients with the initiation of a firstline ART combining at least two molecules active against both HIV and HBV, namely tenofovir (TDF) and lamivudine (3TC) or emtricitabine (FTC) [21] . HBV status ascertainment in HIVinfected patients also contributes to guiding the second-line treatment choice in case of failure of the initial ART. We aimed to measure the proportion of treated HIV-infected patients screened for HBV, to describe changes in HBV screening practices over time, and to assess factors associated with HBV screening in a sample of HIV clinics in West Africa.
Methods

Type of study
We performed a retrospective, multicenter study in several HIV clinics of West Africa that are part of the IeDEA Collaboration (International epidemiological DataBase to Evaluate AIDS)
[23].
Study framework
We selected five French-speaking countries for the study (Benin, Burkina Faso, Ivory Coast, Senegal, and Togo). We selected a university hospital reference center for HIV management in each country. Two urban health clinics with several years of experience in HIV-infected patient management were also selected in Abidjan, Ivory Coast.
Study sample and data collection
Each year, a total of 100 individuals were randomly selected in each clinic (i.e., maximum of 300 patients per clinic) among adult HIV-infected patients (≥18 years) initiated on ART in the participating clinics between January 1, 2010 and December 31, 2012. When the number of patients initiated on ART was <100 for a given year, all patients were selected. Using a standardized questionnaire on HBV screening and management and patients' files, we collected socio-demographic, clinical, and biological data as well as data related to HBV screening practices.
Ethical consideration
This study was approved by the Ethical Committee of each of the five participating countries.
Patient data was computerized using a unique code and no personal identifier was entered into the database. All patients were informed that data collected during routine visits would be collected and used for research purposes.
Statistical analyses
Quantitative variables were expressed as median and interquartile range (IQR). Qualitative variables were expressed as numbers and percentages. The univariate comparison of medians was performed using Kruskal-Wallis test, and that of frequencies using Chi-square test or Fisher's exact test depending on characteristics. The proportion of patients screened for HBV and the prevalence of HBV were calculated with their corresponding 95% confidence interval (95% CI). We used a univariable and then a multivariable logistic regression model to look for factors associated with HBV screening. Data was processed using the STATA software (StataTM 9.0 College Station, Texas, USA).
Results
Study sample
Overall, 2,097 patients were included in the study: 300 in each of the seven facilities, except for the clinic in Dakar, Senegal (n=297). Median age of patients at ART initiation was 37 years 
Reasons for screening
Among the 313 tested patients, HBV screening was systematically performed in 201 patients income-generating activity. Patients for whom such information was lacking were not more often screened for HBV (Table II) .
Prevalence of HBsAg and risk factors
Discussion
This study is one of the first conducted in West Africa to report the proportion of HIV-infected patients screened for HBV and the changes in HBV screening practices over time. Among more than 2,000 patients treated for HIV between 2010 and 2012 in seven urban clinics of West Africa, only 313 (14.9%) were screened for HBV, even though screening practices slightly increased over the three years. We observed substantial differences between countries (a minimum of 4% in Ivory Coast and a maximum of 50% of patients in Senegal). Twenty per cent of patients who had been screened for HBV presented with a chronic HBV infection defined by a positive HBsAg test; 80% of these patients had been prescribed TDF-based ART. Patients aged above 45 years and patients with an income-generating activity were more likely to be screened for HBV than other patients.
As this study was retrospective, we could not: 1) document the prescription of an HBV screening test by physicians; this would have helped assess the proportion of HBV tests actually performed among those prescribed; 2) precisely collect important data to characterize the profile of non-screened patients, especially data related to level of education, occupation, or level of income; 3) collect and precisely describe all reasons for screening (12.5% of missing data for this item).
Findings from our study revealed that despite a recent increase, HBV screening in treated HIVinfected patients is still uncommon in West Africa as only 19% of patients were tested in 2012.
Two factors could explain this low proportion: 1) the delay, at country level, in implementing international and national guidelines on systematic screening for HBV in HIV-infected patients before ART initiation. Most study countries started implementing those guidelines in 2010
following international guidelines issuance, and a period of adjustment was probably needed for them to be widely distributed and for training healthcare professionals, as highlighted by the progressive increase in the proportion of patients screened for HBV over the years. This period of adjustment varied by country and probably resulted in the substantial differences in the results observed in the various study clinics. Conversely, the conduct of HBV prevalence studies in at least one participating clinic may have interfered with routine practices [10] ; 2) as rapid diagnostic tests were not or were poorly available during the study period, HBV screening was mainly based on ELISA tests which relatively high cost was at the expense of patients.
Only well off patients, including those with an income-generating activity, could thus access HBV screening as shown in our study. We did not observe any differences in the proportion of HBV screening by CD4 count levels.
Although international and national guidelines recommend the systematic screening of all HIVinfected patients regardless of their CD4 count, particular attention should be paid to patients with low CD4 count (<200 cells/mm 3 ) or even very low CD4 count (<50 cells/mm 3 ). The absence of HBV screening and adequate management in these patients could be associated with a severe risk of hepatic decompensation due to an immune reconstitution inflammatory syndrome at ART initiation [29] .
The prevalence of HBV infection (positive HBsAg test) observed in our study was 19.8%; this figure is higher than that usually reported in HIV-infected patients in West Africa (8%-15%) [9-11, 13, 30-32] . This difference could be partly explained by our conducting the study in highly specialized university hospitals that manage patients presenting with advanced HIV infection.
Also, our study did not focus on serological monitoring but on collecting data related to HBV screening practices which was far from being systematically performed despite recommendations. A significant proportion of tested patients (14.0%) was thus screened for 
